首页工具

KRN4884

产品编号 T15667 CAS 152802-84-1

KRN 4884 is an opener of the K+ channel. KRN 4884 (0.1-3 μM) activates KATP channels in a concentration-dependent manner (EC50=0.55 μM), in the presence of intracellular ATP (1 mM).

TargetMol的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。

KRN4884, CAS 152802-84-1

规格	价格/CNY	货期
25 mg	￥ 10,600	6-8周
50 mg	￥ 13,800	6-8周
100 mg	￥ 17,500	6-8周

大包装超大折扣，点击咨询

该分子属于定制产品。陶术拥有优秀的合成团队，经验和能力，可以为您提供高性价比的产品。但由于客观因素，研发中会存在小概率合成不成功的情况，还请理解，如您有任何问题，欢迎咨询，我们将竭诚为您服务。

更多批次查询请联系客服

生物活性

化学信息

存储 & 溶解度

参考文献

产品描述	KRN 4884 is an opener of the K+ channel. KRN 4884 (0.1-3 μM) activates KATP channels in a concentration-dependent manner (EC50=0.55 μM), in the presence of intracellular ATP (1 mM).
靶点活性	KATP channel:(EC50)0.55 μM
体外活性	KRN4884 (1 and 3 μM) partially restores the KATP channel activity, after either the spontaneous or Ca2+-induced channel rundown. KRN4884 activates cardiac KATP channels through not only decreasing the sensitivity of the channel to ATP but also directly stimulating the opening of the channel. KRN4884 (0.3 and 3 μM) increases the outward current in a concentration-dependent manner, and the unitary current amplitudes are similar to that of KATP channels in the ATP-free solution. KRN4884 (0.3 μM) shifts the concentration-response relationship for ATP-induced KATP channel inhibition to the right and slightly upward direction without altering the slope. The effect of KRN4884 is augmented by the presence of uridine 5′-diphosphate (3 mM) [1].
体内活性	KRN4884 treatment does not affect serum concentrations of total cholesterol and phospholipid, but increases free fatty acid levels. Rats receiving KRN4884 exhibite an increase in lipoprotein lipase (LPL) activity both in adipose tissue and in skeletal muscle. KRN4884 (3 mg/kg; p.o.; 10 days) treatment, leads to a significant reduction in serum triglyceride levels, which is comparable to that of Clofibrate (160 mg/kg). The effects of KRN4884, a novel pyridinecarboxamidine type KATP channel opener, on serum triglyceride levels are investigated in Sprague-Dawley rats. Reduction in serum triglyceride levels by KRN4884 and Clofibrate are accompanied by a reduction in triglyceride levels both in chylomicron and in very low density lipoprotein [2].

分子量	299.76
分子式	C15H14ClN5
CAS No.	152802-84-1

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

计算器

摩尔浓度计算器

稀释计算器

配液计算器

分子量计算器

质量

浓度

容积

分子量

浓度 (起始)

容积 (起始)

浓度 (终)

容积 (终)

溶液体积

质量

配液浓度

参考文献

1. Shinbo A, et al. Activation of cardiac ATP-sensitive K+ channels by KRN4884, a novel K+ channel opener. J Pharmacol Exp Ther. 1997 Nov;283(2):770-7. 2. Yokoyama T, et al. Effects of KRN4884, a novel pyridinecarboxamidine type KATP channel opener, on serum triglyceride levels in rats. Br J Pharmacol. 1997 Apr;120(8):1471-6.

剂量换算

对于不同动物的给药剂量换算，您也可以参考 更多...

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法：比如您的给药剂量是10 mg/kg，每只动物体重20 g，给药体积100 μL，一共给药动物10 只，您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法：2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL)，如您需要配置的浓度超过该产品的溶解度，请先与我们联系。

体内配方的制备方法：取 50 μL DMSO 主液，加入 300 μL PEG300，混匀澄清，再加 50 μL Tween 80，混匀澄清，再加 600 μL ddH2O, 混匀澄清。

第一步：请输入动物实验的基本信息

剂量

mg/kg

每只动物体重

给药体积

μL

动物数量

第二步：请输入动物体内配方组成，不同的产品配方组成不同，如有配方需求，可先联系我们提供正确的体内配方。

% DMSO+

% +